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Objective: To systematically review brain imaging studies in myotonic dystrophy type 
1 (DM1). 
Methods: We searched Embase (index period 1974 to 2016) and Medline (index 
period 1946 to 2016) for studies in DM1 patients using: MRI, MRS, fMRI, CT, 
ultrasound, PET or SPECT. From 81 studies, we extracted clinical characteristics, 
primary outcomes, clinical-genetic correlations and information on potential risk of 
bias. Results were summarized and we calculated pooled prevalences of imaging 
abnormalities, where possible. 
Results: In DM1, various imaging changes are widely dispersed throughout the 
brain, with apparently little anatomical specificity. We found general atrophy and 
widespread grey matter volume reductions in all four cortical lobes, the basal ganglia 
and cerebellum. The pooled prevalence of white matter hyperintensities is 70% (95% 
CI 64 to 77), as compared to 6% (95% CI 3 to 12) in unaffected controls. DTI shows 
increased mean diffusivity in all four lobes and reduced fractional anisotropy in 
virtually all major association, projection and commissural white matter tracts. 
Functional studies demonstrate reduced glucose uptake and cerebral perfusion in 
frontal, parietal and temporal lobes, and abnormal fMRI connectivity patterns that 
correlate with personality traits. There is significant between study heterogeneity in 
terms of imaging methods, which together with the established clinical variability of 
DM1 may explain divergent results. Longitudinal studies are remarkably scarce. 
Conclusion: DM1 brains show widespread white and grey matter involvement 
throughout the brain, which is supported by abnormal resting state network, 
PET/SPECT and MRS parameters. Longitudinal studies evaluating spatiotemporal 
imaging changes are highly needed. 





Myotonic dystrophy type 1 (DM1) is a complex multisystem disease, characterized by 
significant clinical variability, anticipation and autosomal dominant inheritance.1 Brain 
involvement in DM1 has now been irrefutably demonstrated in neuropsychological, 
neuropsychiatric, and pathologic studies.2 Salient clinical features like apathy, 
cognitive deficits in multiple domains (e.g. visuospatial, executive) and behavioural 
disturbances are important determinants of quality of life.3 At the pathological level, 
cell loss, neurofibrillary tangles and neuronal inclusion bodies occur at various 
locations in the brain.1 Imaging correlates of these clinical and pathological 
characteristics have been addressed in many studies employing a variety of 
methods, with sometimes conflicting results. For example, studies have inconsistently 
found clinical correlates of white matter hyperintensities, in terms of their severity and 
distribution.3 
Therefore, the objective of this study was to provide a comprehensive, widely scoped 
overview of the substantial body of brain imaging literature in DM1 on seven 
commonly used imaging methods (magnetic resonance imaging (MRI), functional 
magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS), 
ultrasound, single-photon emission computed tomography (SPECT), positron 
emission tomography (PET) and computed tomography (CT)). In addition, we 
evaluated the reported relationships between imaging and clinical - genetic 
parameters in DM1 patients. Finally, we evaluated evidence on temporal changes in 
DM1 brain imaging (i.e. longitudinal studies), to assess whether these were in 
support of the view on DM1 as a progressive neurodegenerative disease.  
Methods 
Search 




We searched Embase (index period 1974 to 2016) and Medline (index period 1946 to 
2016) for relevant studies. We searched for free text and index terms related to DM1 
and imaging methods (Appendix e-1A and e-1B). Our primary search was completed 
on June 22nd, 2016, with a final update yielding three additional studies performed 1st 
September, 2016. We also performed cross-referencing to identify articles potentially 
missed by our search. 
Eligibility criteria 
We selected studies on the basis of predefined criteria for eligibility, considering 
studies reporting on DM1 patients and at least one brain imaging method (Appendix 
e-2). We restricted our selection to studies that utilized CT, MRI, MRS, SPECT, PET, 
fMRI or ultrasound methods. Reasons for exclusion of studies were case reports (on 
single patients), double reporting, and studies written in a language different from 
English, French, German or Dutch. We also excluded studies for which we were 
unable to obtain full-text. Study selection comprised an initial round of title and 
abstract screening, after which a second round of full-text screening was performed. 
All (n = 14) conference abstracts were excluded. 
Data extraction 
A data extraction form was piloted on five studies and consequently adapted where 
necessary. We extracted clinical information such as age, sex, educational level, 
types of DM1 (congenital, juvenile, adult-onset), main inclusion- and exclusion 
criteria, and the use of neuropsychological tests and questionnaires for psychiatric 
disorders. Type of DM1 was arbitrarily defined as presence of first clinical symptoms 
at birth (congenital DM1 (cDM1)), after birth but before age of 18 years (juvenile 
(jDM1)) or at 18 years or later (adult-onset (aDM1)). If reported, the estimated age at 




onset and disease duration were recorded. Furthermore, we recorded for each study: 
imaging method used, technical details and the main findings (see section on ‘data 
synthesis’). 
Quality assessment 
We adopted a quality assessment form from Kmet and colleagues, with modifications 
to better suit the requirements of this review (Appendix e-3).4, 5 A single author (KO) 
scored all studies for quality and risk of bias on a scale of 0, 1 or 2 (0 representing 
the worst and 2 representing the best score). 
Data synthesis 
We classified studies by their reporting of either structural or functional imaging data, 
or both. Structural data comprised structural MRI, CT and ultrasound studies; 
whereas fMRI, SPECT, PET and MRS were classified under functional imaging. For 
structural MRI studies, we subdivided and separately aggregated data into three 
categories: whole brain (atrophy and/or ventricular enlargement), grey matter 
(volume; cortical thickness), and white matter (white matter hyperintensities (WMH) 
and integrity of normal-appearing white matter (NAWM)). We clustered results per 
brain region (i.e. brain lobes versus deep brain structures and cerebellum; cortical 
versus subcortical). CT studies were evaluated for information on atrophy (focal or 
global), ventricular dilatation and skull hyperostosis. We evaluated ultrasound studies 
for findings of ventricular dilatation, and changes of brainstem echogenicity. Results 
were assessed in a qualitative manner for all modalities, except WMH on MRI, which 
allowed a pooled analysis. We estimated pooled WMH prevalence across brain 
regions using metaXL (version 5.3, EpiGear International Pty Limited, Queensland, 
Australia), giving a random-effects weighted mean prevalence with 95% confidence 




intervals (95% CI). We calculated the I2 statistic as a measure for statistical 
heterogeneity. For functional imaging studies, aggregation of data was unfeasible 
due to a limited number of studies per imaging technique and heterogeneous 
methods. 
Results 
Search and selection results 
Our search and selection process yielded a total of 81 included studies (table 1). The 
most important reasons for excluding studies were double reporting (n = 11), non-
availability of full-text (n = 15) or unsuitable publication type (n = 13) (supplemental 
Appendix e-4). Language restrictions applied to most studies for which full-text was 
unavailable.  
Demographics and disease characteristics 
Eighty-one studies included a total of 1,663 DM1 cases (Appendix e-5A). Twenty-
three studies only analyzed DM1 cases, whereas 58 studies included a total of 1,334 
unaffected controls. In studies reporting sex, there was an excess of male DM1 
cases (865 males (53.4%) versus 754 females (46.6%), χ2 = 7.62, p = 0.006). The 
median of average ages across the studies was 38.5 years, interquartile range (IQR) 
of 5.9 years and total range of 5 to 56.6. Median age at onset was 25.7 years (IQR 
5.8 years). In 31 studies reporting modal CTG repeat length, median repeat length 
was 582 repeats (IQR 177 and total range 534 to 719 repeats). For 27 studies 
providing information on the muscular impairment rating scale (MIRS), median score 
was 3.1 (IQR 0.43), which indicates distal but no proximal weakness. Forty-one 
imaging studies (51%) performed neuropsychological testing (Appendix e-7D). 
Regarding disease classification, presence or absence of cDM1, jDM1 and aDM1 




was reported in respectively 57, 60 and 60 studies. Nineteen studies reported 
presence of cDM1 patients, whereas jDM1 and aDM1 patients were included in 48 
and 52 studies, respectively. With the exception of MRS, functional imaging studies 
did not include cDM1 patients. In structural studies, cDM1 participants often 
comprised a minority of included participants (data not shown). 
Quality analysis 
Our analysis demonstrated that most studies had a clearly described research 
question (i.e. score 2, n = 70), included participants with firmly established diagnosis 
(both before and after gene identification in 1992) (i.e. score 2, n = 70), and provided 
sufficient details on participants characteristics (i.e. score 2, n = 72), imaging protocol 
and analysis (i.e. score 2, n = 71)(Appendix e-5B). Twenty-two studies (27%) gave a 
full (i.e. score 2) description of the recruitment procedure, and six (7%) provided 
information on the rates of participation. In- and exclusion were provided (i.e. score 1 
or 2) in 54 studies (67%); 53 studies took into account (i.e. score 1 or 2) possible 
confounding factors. We found discussions of study limitations in a minority of the 
publications included in our review (i.e. score 1 or 2; n = 27, 33%). 
Structural imaging studies 
A total of 1,247 DM1 cases and 1,015 healthy controls were included in 65 and 46 
structural MRI studies, respectively (summary of outcomes parameters, methods of 
assessment and most salient findings in table 2, figures 1 and 2).6-69 Of note, only 
one MRI study had a longitudinal design.18  
Whole brain. Irrespective of the method of analysis, the large majority of studies 
found generalized atrophy in DM1 participants compared to healthy controls (table 2). 




Grey matter. Grey matter volumes were mostly assessed with semi-automated or 
fully automated methods (voxel-based morphometry (VBM)) (table 2). Nine studies 
used voxel-based morphometry in DM1, showing a pattern of widespread reduction 
of grey matter volume in DM1 cases compared to controls. Reduction of grey matter 
volume was found in frontal (n = 9 out of 9), temporal (n = 7 out of 9), parietal (n = 8 
out of 9) and occipital cortices (n = 7 out of 9), as well as to deep grey matter 
structures (n = 8 out of 9) and cerebellum (n = 3 out of 4). The data did not allow for 
analyses of atrophy in areas within lobes, or within specific deep grey matter 
structures. Comparing cortical thickness between DM1 and control brains (n = 1 
study comprising 24 patients), reduced cortical thickness was demonstrated in 
parietal-occipital cortex bilaterally, as well as in unilateral (left or right) frontal and 
temporal cortex.68 
White matter. We calculated the pooled prevalence (pp) of WMH across 49 studies 
that provided sufficient data for analysis. We found a pp of 70.4% (95% CI = 63.8 to 
76.5%), with substantial statistical heterogeneity (I2 = 77%). Fifteen studies also 
reported the prevalence of white matter hyperintensities in (age- and sex matched) 
controls, with a pp of 6.4% (95% CI = 2.5 to 11.7%). WMH in DM1 patients were 
located in periventricular and subcortical white matter, preferentially in frontal (pp 
52%, 95% CI = 38 to 65%, I2 = 54%), temporal (pp 44%, 95% CI = 31 to 58%, I2 = 
49%) and parietal lobes (pp 31%, 95% CI = 23 to 40%, I2 = 12%), although they were 
also noted to occur in the occipital lobe in eight studies. Anterior temporal pole (i.e. 
‘deep temporal’; Figure 2)) WMH were reported in 12 studies, of which 10 provided 
sufficient information to calculate a pooled prevalence of 30.3% (95% CI = 17.3% to 
45.0%; I2 = 82%). WMH volume/lesion load across studies was difficult to aggregate 
because of differences in methodology and reporting (summarized in Appendix e-6). 




Besides WMH, enlarged Virchow-Robin spaces were shown to be more prevalent in 
DM1 cases than in unaffected controls in four studies (data not shown).  
The structural integrity of the normal-appearing white matter was mostly evaluated by 
means of diffusion tensor imaging (table 2). Studies utilizing region-of-interest (ROI) 
approaches and tract-based spatial statistics (TBSS) demonstrated widespread 
reduction of fractional anisotropy (FA) and increase in mean diffusivity in DM1 
patients compared to controls. Specifically, ROI approaches demonstrated FA 
reduction in all four lobes and some predefined fiber tracts (e.g. inferior and superior 
longitudinal fasciculus, uncinate fasciculus, forceps minor and major, cingulum). 
TBSS studies showed mostly symmetrical decreased FA in all major association, 
projection and commissural fibers. 
Ten CT studies (1983 to 2013) included a total of 162 DM1 cases and 122 unaffected 
individuals.12, 58, 70-77 These studies studies focused on the presence of ventricular 
dilatation (present in 1 out of 19 to 6 out of 7 patients), general atrophy (present in 3 
out of 19 to 22 out of 37 patients) and frontal hyperostosis (10 out of 37 to 14 out of 
16 patients). Two uncontrolled ultrasound studies examined 24 newborn congenital 
DM1 patients and found ventricular dilatation and macrocephaly in the majority of 
patients (11 out of 14 and 8 out of 10, respectively).78, 79 Two ultrasound studies 
reported increased third ventricle diameter and mixed results for brainstem 
echogenicity in (mostly) adult DM1 cases versus controls.41, 80  
Functional imaging studies 
Seven PET studies demonstrated a consistent global decrease in glucose uptake as 
well as regional reductions (i.e. lobe specific) compared to unaffected controls (table 
3).45, 63, 69, 81-84 Controlling for possible volumetric differences in two of these studies 




did not alter the results.63, 69 Five SPECT studies demonstrated a picture in line with 
findings from PET studies, demonstrating both globally and regional decreases (i.e. 
lobe specific) in cerebral perfusion in DM1 cases compared to unaffected controls 
(table 3).16, 53, 60, 84, 85 In fMRI studies, an altered activation pattern in bilateral motor 
regions was demonstrated in DM1 patients during a motor task and in the presence 
of clinical myotonia.13, 86 Abnormal resting-state functional connectivity in default-
mode and ‘theory-of-mind’ networks was also noted in relation to personality traits 
and social cognition in DM1 (table 3).56, 87 The most consistent finding in MRS studies 
was a decrease in N-acetylaspartate (NAA) (table 4).8, 17, 35, 62, 88 
Correlation of imaging with genetic and clinical parameters 
Twenty-seven studies examined a total of 53 correlations between imaging findings 
and modal CTG repeat length in blood, with 15 significant correlations found in 10 
studies (Appendix e-7A). In general, longer CTG repeats were associated with 
greater structural and functional changes of the brain. However, variations in imaging 
modalities and statistical tests (e.g. linear regression, parametric or non-parametric 
correlation coefficients) limited comparisons between studies. We found correlational 
analyses between imaging findings with age and duration of disease in 28 and 27 
studies, totaling 43 and 45 associations, respectively (Appendix e-7B and e-7C). 
Significant simple (i.e. Pearson or non-parametric equivalent) correlations for age (16 
out of 43) and disease duration (20 out of 45) with imaging changes ranged from 
small (~0.3) to strong (~0.7) and most frequently concerned white matter lesions. 
Evaluation of correlations with neuropsychological testing failed to yield consistent 
relationships (Appendix e-7D). For example, neuropsychological studies in DM1 have 
shown consistent deficits on visuoconstruction domain as demonstrated by the Rey-
Osterrieth Complex Figure Copy Test (ROCF-C) (authors’ data, unpublished). 




However, only three out 15 correlational analyses employing the ROCF-R found 
significant relations between imaging findings and tests results (Appendix e-7D).11, 53 
Discussion 
In DM1, there is a broad spectrum of imaging changes that are widely dispersed 
throughout the brain, with apparently little anatomical specificity. Our findings are in 
line with the wide range of clinical, molecular and histopathological brain alterations 
previously reported.89, 90 Significant between study heterogeneity in terms of imaging 
methods, together with the established clinical variability of DM1 may explain 
divergent results. At the structural level, we found evidence for general brain atrophy, 
which corroborates histopathology studies demonstrating diffuse cerebral atrophy.91, 
92 Partly, brain atrophy can be attributed to volume loss of grey matter, which is 
evident in all lobes, deep grey matter and cerebellum in VBM studies. Notably, VBM 
is best suited for the evaluation of cortical changes, less so for deep grey matter 
structures for reasons mainly related to tissue segmentation.93, 94 In addition, the 
cerebellum is often not analyzed in VBM studies. Also, age factor, corrected in 5 out 
of 9 studies may have influenced the results. Possible explanations for grey matter 
volume loss are speculative, but may include neuronal loss and loss and/or 
decreased genesis of dendritic spines and synapses.92, 95 The possibility of neuronal 
loss is corroborated by MRS studies that show decreases in [NAA] in grey matter, a 
marker for neuronal density.  
White matter involvement in DM1 involves T2/FLAIR hyperintensities preferentially 
located in frontal, temporal and parietal lobes at periventricular and subcortical 
locations. Compared to matched healthy controls, DM1 patients have a higher 
frequency of WMH. The temporo-polar WMH, reported to be relatively specific for 
DM1, are present in approximately one third of patients. Divergent prevalence (70.4% 




(95% CI = 63.8 to 76.5%); I2: 77%) of WMH across studies may be the result of study 
characteristics such as field strength (e.g. 1.5 T versus 3 T), imaging sequence (e.g. 
T2 versus FLAIR), voxel-sizes and other methodological parameters.96 More 
importantly, differences between studies might relate to variations between study 
populations in terms of age, DM1 disease class and severity and CTG repeat length. 
Besides WMH, there is now substantial evidence for diffuse involvement of NAWM, 
as mainly demonstrated by DTI techniques. Notably, all DTI studies used a similar 
method of controlling for family-wise error at the p < 0.05 threshold. Future studies 
applying more stringent thresholding might theoretically uncover a more focal pattern 
of white matter involvement. Nonetheless, it is likely that damage to structural brain 
networks results in alterations in functional connectivity that has recently been 
demonstrated in DM1.56, 87 These studies are critically important for better 
understanding of imaging correlates of neuropsychological involvement in DM1. The 
lack of consistent correlations found to date may result from limited power due to 
small sample sizes, and from the fact that cognitive functions are not anatomically set 
to one particular brain region, but rather are a consequence of complex network 
interactions.97 
With regard to the etiology of white matter damage, we cannot exclude a role for 
‘traditional’ vascular risk factors as less than half of the studies took into account 
these confounders and some risk factors (e.g. smoking, hypercholesterolemia) have 
been shown to be highly prevalent in DM1.98, 99 However, the presence of temporal 
and temporo-polar WMH argue against a solely cardiovascular etiology of WMH in 
DM1. Interestingly, the pattern of WMH concurs with the predominantly frontal, 
temporal and parietal anomalies observed with PET and SPECT imaging, suggesting 
a possible role for decreased perfusion in the etiology of WMH. An important caveat 




is the fact that none of the SPECT and only two out of the seven PET studies 
corrected for atrophy. Nevertheless, these studies are notable for the fact that 
changes in frontal perfusion corroborate clinical frontal lobe involvement, such as 
apathy and disorders of executive functioning.3 It remains speculative whether 
perfusion deficits are a cause or consequence in DM1 pathophysiology: neuronal 
dysfunction/loss may lead to decreased metabolic demands; alternatively perfusion 
deficits may be causal to tissue damage and dysfunction. 
The paucity of longitudinal imaging studies (3 out of 81) in DM1 is striking given the 
chronic nature and relatively long survival in the disease and especially because 
many of the neuroimaging findings discussed here (e.g. brain atrophy, WMH) are 
associated with age in the general population.100-102 Whether imaging anomalies in 
DM1 have a specific spatiotemporal pattern (i.e. start in certain anatomical region(s) 
and disseminate over the brain with time) should be tested in future studies. Such 
progressive nature of brain involvement in DM1 is suggested by neuropsychological 
studies documenting cognitive decline in some (e.g. attention, psychomotor speed, 
executive functions) but not all cognitive domains over many months to years.103, 104  
Complex interrelations between clinical and genetic parameters may explain the lack 
of an effect of age, disease duration and length of repeat on neuroimaging findings 
one would expect in a neurodegenerative disease. Anticipation in DM1 is extreme, 
with age at onset typically decreasing by 20 to 30 years per generation.105 Coupled 
with the sex-dependent mutational dynamics, anticipation in DM1 leads to a family 
structure that is highly non-random in terms of age, inherited CTG repeat length and 
disease severity.105-108 Thus, individuals recruited from the first generation of known 
DM1 families have only a mild presentation of disease despite that fact that they are 
usually relatively old before the disease is diagnosed in their family. Conversely, 




individuals from later generations, despite being younger, usually have inherited a 
much larger CTG repeat and thus present with a more severe form of the disease. As 
a result, the true effects of age and inherited CTG length are masked by their inverse 
relationship in the patient population. Moreover, somatic instability of the DMPK CTG 
repeat that is age- and tissue-dependent and expansion-biased, could lead to longer 
modal CTG repeats in blood DNA of older individuals and have a negative impact on 
the precision of genotype-phenotype relationships.109-112 The CTG repeat is also 
somatically unstable in other tissues, including post-mitotic tissues (e.g. brain) and it 
has been suggested that somatic expansion may contribute, at least in part, to the 
tissue specificity and progressive nature of the symptoms.109-112 It should be noted 
that with the exception of cerebellum, average CTG repeat lengths are thousands of 
repeats longer than the inherited allele length in various regions of the brain.92, 113, 114 
Thus, it may not be surprising that pathology in the DM1 brain is widespread and 
diffuse. 
Limitations and future directions 
Our study has several limitations. A single author performed literature search and 
selection. Although we also performed cross-referencing by two authors, we cannot 
exclude the possibility of missed studies. Selection preferences of reviewed studies 
may have biased recruitment towards participants with obvious CNS involvement or 
away from individuals with apathy, thus limiting the generalisability of our findings. 
Moreover, selection preferences and the sampling biases discussed earlier preclude 
the identification of relevant differential phenotypes in the DM1 population that could 
help to explain heterogeneity in our results. The latter is also impeded by the 
absence of a universally accepted and adopted disease classification (e.g. 
congenital, childhood, juvenile, adult, late-onset DM1) across studies.  




Our study underlines the need for a large, imaging study of long duration (i.e. 
preferably ≥10 years) including genetically and clinically well characterized 
participants. Ideally, recruitment and source of participants would be carefully 
described and potential sources of confounding (e.g. vascular risk factors) accounted 
for. International collaboration, as exemplified by the European OPTIMISTIC trial in 
DM1,  will increase generalisability of results and statistical power.115 Not only will 
such a study provide better insight into natural history, but it will also allow to 
determine which imaging parameters are suitable as outcome markers in future 
clinical trials. 
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CT 169 85 23 10 10 
MRI 365 173 94 75 64 
MRS 40 51 7 5 5 
Ultrasound 11 6 5 4 4 
fMRI 10 5 4 4 4 
PET 19 15 6 6 7 
SPECT 33 23 6 6 6 
Legend. Search and selection results. Studies found in search and remaining after deduplication and 
title and abstract screening. The numbers in the final column do not add up to 81 as some studies 
utilized more than one imaging method. 
  





Summary of structural MRI studies in DM1 
Parameter Study ID Main findings 
Whole brain volume 
Unknown method of assessment (n = 7) 9, 14, 35, 37, 53, 56, 69 Generalized brain atrophy in DM1 patients 
compared to healthy controls in almost all studies. 
Subjective visual assessment (n = 9) 18, 21, 27, 38, 42, 47, 67, 68, 77  
Ventricle brain-ratio or comparable brain 
measurements (n = 13) 
2, 7, 9, 13, 17, 19, 20, 22, 23, 24, 
36, 49, 72  
(Semi-) automated segmentation 
methods (n = 8) 
3, 8, 33, 39, 44, 45, 74, 76 
Grey matter 
(Semi-automated) segmentation 
methods (n = 2) 
29, 33 Reduction of grey matter volumes in frontal, 
temporal, parietal and occipital cortex. Reduction 
of grey matter volume in deep grey matter 
structures and cerebellum. Reduced cortical 
thickness in parietal, frontal and temporal lobes. 
Voxel-based morphometry (n = 9) 5, 8a, 12a, 51, 54, 63a, 64, 76, 81a 
Cortical thickness analysis (n = 1) 81 




White matter - White matter hyperintensities 
Prevalence of white matter 
hyperintensities (n = 49) 
1, 2, 3, 5, 7, 9, 11-14, 17-27, 30, 33 
- 37, 40, 41, 42, 44-47, 49, 53, 56, 
58, 62, 66-69, 71, 72, 74, 76, 77, 
81 
Increased prevalence of WMH (subcortical, deep 
white matter, periventricular) in DM1 patients 
compared to healthy controls, particularly in 
frontal>temporal>parietal lobes. Temporo-polar 
WMH in one third of participants. Increased lesion 
load in patients versus healthy controls. 
Total lesion load (TLL) or total lesion 
area (TLA) of WMH (n = 8) 
5, 7, 8, 11, 12, 63, 64, 81 
Fazekas scale (n = 2) 8, 77 
ARWMC/ Wahlund scale (n = 6) 12, 51, 62, 63, 64, 65 
White matter - Normal appearing white matter evaluation 
T2-relaxometry (n = 1) 23 Widespread reductions in FA and increase in 
mean diffusivity throughout white matter: 
projection, association and commissural fibers. 
Alterations of T2 relaxation demonstrated 
throughout white matter. Mixed results of 
magnetization transfer ratios of white matter. 
Magnetization transfer (n = 2) 33, 52 
DTI – ROI approach (n = 6) 29, 30, 54, 78, 79, 80 
DTI – TBSS (n = 5) 8, 12, 51, 64, 81 
Legend. Summary of structural MRI studies in DM1. MRI studies evaluating whole brain volume/atrophy; grey matter volumes/atrophy and white matter 
integrity. ARWMC: age-related white matter change scale; DTI diffusion tensor imaging; ROI: region of interest; TBSS tract-based spatial statistics; prevalence 




denotes the ratio of patients with WMH versus total number of patients; TLL and TLA refer to automated methods to detect WMH volume. For study ID, please 
refer to Appendix e-5. Superscript a denotes VBM studies that corrected for age.





Summary of imaging findings in DM1 
Skull/Cranial Vault
· Hyperostosis
· Whole brain atrophy
· Increased ventricular 
volume
Grey matter
· Widespread volume 
reduction of cortical and 
deep grey matter







· Widespread reduced 
FA, increased MD in 
projection, association 
and commissural fiber 
systems




Reduced whole brain 
perfusion and glucose 
uptake; reduced perfusion 




Reduced NAA/Cr in 
multiple cortical regions
fMRI
Alterations in central motor 





Legend. Summary of structural and functional imaging findings in DM1. A: T2-weighted transversal 
MRI of a 54-year old male adult onset DM1 patient with demonstrated hydrocephalus. B: Transversal 
FLAIR MRI in a 30 year old female adult onset DM1 patient showing bilateral temporo-polar WMH. 
This patient also had posterior fossa surgery for hemangioblastoma. WMH: white matter 
hyperintensity; FA: fractional anisotropy; MD: mean diffusivity; NAA: N-acetylaspartate; Cr: creatine; 
PET: positron emission tomography; SPECT: single photon emission computed tomography; MRS: 
magnetic resonance spectroscopy; fMRI: functional MRI. 
  





Illustrative images of structural DM1 imaging 
 
Legend. Illustrative CT and MRI images of DM1 patients from our centre. A: CT-scan showing frontal 
atrophy in a 20-year old male juvenile onset DM1 patient. B: T1-weighted axial MRI demonstrating 
frontoparietal atrophy in a 60-year old male adult onset DM1 patient. C: Hyperostosis (most 
prominently frontally located) in a 46-year old adult onset female DM1 patient. D+F: Subcortical and 
periventricular WMH in a 53-year old adult onset DM1 patient without known risk factors for 
cardiovascular disease. Note the guirlande-shaped WMH at the convexity (D) and left temporo-polar 
WMH (F) which argue against a chronic ischemic etiology. 
  





Functional imaging studies in DM1 
Legend. Functional imaging studies in DM1. ID: study identification numbers (Appendix e-5). No.: 
number, PET: positron emission tomography, SPECT: single photon emission computed tomography, 
fMRI: functional MRI, DMN: default mode network 
  






PET 4, 28, 47, 50, 
58, 61, 76 
7 97/121 Decreased whole brain glucose 
uptake; decreased uptake in frontal 
and parietal lobes, and temporal 
lobes, basal ganglia and 
hypothalamus 
SPECT 15, 48 , 61, 
62, 71 
5 108/42 Decreased whole brain perfusion; 
decreased perfusion in frontal, 
temporal and parietal lobes 
fMRI 11, 65, 66, 73 4 78/49 Alterations in central motor system 
activation and resting-state 
functional connectivity (DMN and 
‘theory-of-mind’ networks)  





Magnetic resonance spectroscopy findings in myotonic dystrophy type 1 






Echo time Main findings 
37 5 right parietal region, 
occipital and frontal 
1.5 T 270 ms NAA/Cho↓ and 
NAA/Cr↓ 
14 14 midoccipital grey matter, 
temporoparietal grey 
matter 
1.5 T 30 ms NAA =, MI↑, Cho↑, 
Cr↑;  NAA/Cr↓, 
Cho/Cr = 
3 21 insular cortex (frontal, 
temporal, parietal 
opercula) 
1.5 T 19 ms NAA/Cr↓; NAA/Cho 
↓; Cho/Cr = 
74 14 midoccipital grey matter, 
temporoparietal  grey 
matter, frontal white 
matter 
1.5 T 135 ms NAA ↓, Cr =/↓, Cho 
=/↓; Naa/Cr↓, 
Cho/Cr = 
70 14 White matter:  frontal, 
corona radiata, parietal; 
posterior internal capsule  
Grey matter: basal 
ganglia, thalamus, limbic 
cortex 
3.0 T 24 to 30 
ms 
grey matter: NAA↓, 
Cho↑, Cr =; 
NAA/Cr↓ 
white matter:  NAA↓, 
Cho↓, Cr=; 
NAA/Cr↓; Cho/CR = 
Legend. Magnetic resonance spectroscopy findings in DM1. NAA N-acetylaspartate; MI: myo-inositol; 
Cr: creatine; Cho: choline; = not different from controls; ↓/↑ decreased or increased compared to 




controls; T: Tesla; ms: milliseconds; only the most frequently evaluated metabolites are presented in 
the table. 
 
